Biopharmaceutical company Alector Inc. announced that it will discontinue its Phase II PROGRESS-AD clinical trial of its candidate drug Nivisnebart (development code AL101/GSK4527226) for the treatment of early-stage Alzheimer's disease.
Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
This decision is based on a pre-planned interim analysis, which showed that the trial failed to meet the expected efficacy endpoints.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now！
You may also like
Swiss Franc: Range trading persists against US Dollar – UOB
FXStreet•2026/10/14 11:45
BUZZ - US stock market updates: Liquidia, GameStop, Bank of America, BlackRock
路透社•2026/10/14 11:36
Crypto prices
More
Bitcoin
BTC
$83,576.37
+0.46%
Ethereum
ETH
$2,507.88
+0.40%
Tether USDt
USDT
$0.9989
+0.01%
BNB
BNB
$741.72
+0.47%
XRP
XRP
$1.38
+1.37%
USDC
USDC
$0.9998
-0.02%
Solana
SOL
$107.3
+1.17%
TRON
TRX
$0.3336
+1.61%
Zcash
ZEC
$1,245.1
+5.05%
Hyperliquid
HYPE
$81.93
+0.30%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now